Correction to Press Release Announcing Reverse Stock Split of Rallybio Common Stock in Connection with the Proposed Merger with Avenzo
Key Highlights
- ➤Reverse split corrected to become effective at 4:01 p.m. ET November 20, 2026
- ➤Rallybio trading expected to begin post-reverse split basis November 23, 2026
- ➤One-for-two reverse split tied to proposed Avenzo merger
- ➤Proposed merger could face delays or fail if closing conditions remain unmet
Correction to Press Release Announcing Reverse Stock Split of Rallybio Common Stock in Connection with the Proposed Merger with Avenzo
Rallybio Corporation (Nasdaq: RLYB) today announced a correction to its press release issued November 10, 2026. The prior press release incorrectly stated that the one-for-two reverse stock split of Rallybio’s issued and outstanding common stock in connection with the transactions contemplated by the Agreement and Plan of Merger and Reorganization, dated as of May 31, 2026, among Rallybio, Avenzo Therapeutics, Inc. and Farmington Merger Sub, Inc. is expected to become effective at 12:01 a.m., Eastern Time, on November 20, 2026. The reverse split is actually expected to become effective at 4:01 p.m., Eastern Time, on November 20, 2026 and is expected to start trading on a post-reverse stock split basis on November 23, 2026.
Get started
Create a free account to read the full story.